k252 a Search Results


93
Alomone Labs k252a
K252a, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/k252+a/K252a/pm28184413-71-8-9
Average 93 stars, based on 1 article reviews
k252a - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

93
Cell Signaling Technology Inc k252a
Changes in the mechanical threshold after antagonist administration. a Compared to the CYP + DMSO groups, ANA-12 (0.5 mg/kg), and ANA-12 (1.0 mg/kg) treated every other day after CYP injection reduced the decrease in the mechanical threshold and accelerated recovery significantly, while there was no difference between ANA-12 (0.1 mg/kg) and CYP + DMSO group. There was difference between ANA-12 (0.5 mg/kg) and ANA-12 (1.0 mg/kg) only at day 7, day 10, day 13. b Compared to the CYP+DMSO groups, ANA-12 (0.5 mg/kg), and <t>K252a</t> treated every other day after CYP injection reduced the decrease of the mechanical threshold and accelerated recovery significantly, and there was no difference between the effects of ANA-12 (0.5 mg/kg) and K252a. c ANA-12 treated next day after the third CYP injection 3 days continuously could reverse the mechanical threshold rapidly. d ANA-12 treated one day prior to CYP injection could prevent the onset of allodynia; moreover, there was no significant difference when compared with the control group. All data were analyzed using a two-way analysis of variance (ANOVA) followed by the Sidak's multiple comparisons test. All data were calculated as mean ± SEM ( n = 10 per group). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. the control group. # p < 0.05, ## p < 0.01, ### p < 0.001 vs. the CYP + DMSO group. && p < 0.01, &&& p < 0.001 vs. the ANA-12 (0.5mg/kg) group
K252a, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/k252+a/K252a/pmc06958761-41-0-5
Average 93 stars, based on 1 article reviews
k252a - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

85
LKT Laboratories trk b inhibitor
Changes in the mechanical threshold after antagonist administration. a Compared to the CYP + DMSO groups, ANA-12 (0.5 mg/kg), and ANA-12 (1.0 mg/kg) treated every other day after CYP injection reduced the decrease in the mechanical threshold and accelerated recovery significantly, while there was no difference between ANA-12 (0.1 mg/kg) and CYP + DMSO group. There was difference between ANA-12 (0.5 mg/kg) and ANA-12 (1.0 mg/kg) only at day 7, day 10, day 13. b Compared to the CYP+DMSO groups, ANA-12 (0.5 mg/kg), and <t>K252a</t> treated every other day after CYP injection reduced the decrease of the mechanical threshold and accelerated recovery significantly, and there was no difference between the effects of ANA-12 (0.5 mg/kg) and K252a. c ANA-12 treated next day after the third CYP injection 3 days continuously could reverse the mechanical threshold rapidly. d ANA-12 treated one day prior to CYP injection could prevent the onset of allodynia; moreover, there was no significant difference when compared with the control group. All data were analyzed using a two-way analysis of variance (ANOVA) followed by the Sidak's multiple comparisons test. All data were calculated as mean ± SEM ( n = 10 per group). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. the control group. # p < 0.05, ## p < 0.01, ### p < 0.001 vs. the CYP + DMSO group. && p < 0.01, &&& p < 0.001 vs. the ANA-12 (0.5mg/kg) group
Trk B Inhibitor, supplied by LKT Laboratories, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/k252+a/K252a/pmc03578719-38-6-9
Average 85 stars, based on 1 article reviews
trk b inhibitor - by Bioz Stars, 2026-09
85/100 stars
  Buy from Supplier

90
Biomol GmbH k252a
Changes in the mechanical threshold after antagonist administration. a Compared to the CYP + DMSO groups, ANA-12 (0.5 mg/kg), and ANA-12 (1.0 mg/kg) treated every other day after CYP injection reduced the decrease in the mechanical threshold and accelerated recovery significantly, while there was no difference between ANA-12 (0.1 mg/kg) and CYP + DMSO group. There was difference between ANA-12 (0.5 mg/kg) and ANA-12 (1.0 mg/kg) only at day 7, day 10, day 13. b Compared to the CYP+DMSO groups, ANA-12 (0.5 mg/kg), and <t>K252a</t> treated every other day after CYP injection reduced the decrease of the mechanical threshold and accelerated recovery significantly, and there was no difference between the effects of ANA-12 (0.5 mg/kg) and K252a. c ANA-12 treated next day after the third CYP injection 3 days continuously could reverse the mechanical threshold rapidly. d ANA-12 treated one day prior to CYP injection could prevent the onset of allodynia; moreover, there was no significant difference when compared with the control group. All data were analyzed using a two-way analysis of variance (ANOVA) followed by the Sidak's multiple comparisons test. All data were calculated as mean ± SEM ( n = 10 per group). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. the control group. # p < 0.05, ## p < 0.01, ### p < 0.001 vs. the CYP + DMSO group. && p < 0.01, &&& p < 0.001 vs. the ANA-12 (0.5mg/kg) group
K252a, supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/k252+a/k252a/10__1523_slash_jneurosci__17___14___05445__1997-41-0-6
Average 90 stars, based on 1 article reviews
k252a - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
BioMimetic Therapeutics synthesis of (+)-k252a
Changes in the mechanical threshold after antagonist administration. a Compared to the CYP + DMSO groups, ANA-12 (0.5 mg/kg), and ANA-12 (1.0 mg/kg) treated every other day after CYP injection reduced the decrease in the mechanical threshold and accelerated recovery significantly, while there was no difference between ANA-12 (0.1 mg/kg) and CYP + DMSO group. There was difference between ANA-12 (0.5 mg/kg) and ANA-12 (1.0 mg/kg) only at day 7, day 10, day 13. b Compared to the CYP+DMSO groups, ANA-12 (0.5 mg/kg), and <t>K252a</t> treated every other day after CYP injection reduced the decrease of the mechanical threshold and accelerated recovery significantly, and there was no difference between the effects of ANA-12 (0.5 mg/kg) and K252a. c ANA-12 treated next day after the third CYP injection 3 days continuously could reverse the mechanical threshold rapidly. d ANA-12 treated one day prior to CYP injection could prevent the onset of allodynia; moreover, there was no significant difference when compared with the control group. All data were analyzed using a two-way analysis of variance (ANOVA) followed by the Sidak's multiple comparisons test. All data were calculated as mean ± SEM ( n = 10 per group). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. the control group. # p < 0.05, ## p < 0.01, ### p < 0.001 vs. the CYP + DMSO group. && p < 0.01, &&& p < 0.001 vs. the ANA-12 (0.5mg/kg) group
Synthesis Of (+) K252a, supplied by BioMimetic Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/k252+a/synthesis+of+++++k252a/us07038043-147-7-4
Average 90 stars, based on 1 article reviews
synthesis of (+)-k252a - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
U73122 PLC k252a trka
Changes in the mechanical threshold after antagonist administration. a Compared to the CYP + DMSO groups, ANA-12 (0.5 mg/kg), and ANA-12 (1.0 mg/kg) treated every other day after CYP injection reduced the decrease in the mechanical threshold and accelerated recovery significantly, while there was no difference between ANA-12 (0.1 mg/kg) and CYP + DMSO group. There was difference between ANA-12 (0.5 mg/kg) and ANA-12 (1.0 mg/kg) only at day 7, day 10, day 13. b Compared to the CYP+DMSO groups, ANA-12 (0.5 mg/kg), and <t>K252a</t> treated every other day after CYP injection reduced the decrease of the mechanical threshold and accelerated recovery significantly, and there was no difference between the effects of ANA-12 (0.5 mg/kg) and K252a. c ANA-12 treated next day after the third CYP injection 3 days continuously could reverse the mechanical threshold rapidly. d ANA-12 treated one day prior to CYP injection could prevent the onset of allodynia; moreover, there was no significant difference when compared with the control group. All data were analyzed using a two-way analysis of variance (ANOVA) followed by the Sidak's multiple comparisons test. All data were calculated as mean ± SEM ( n = 10 per group). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. the control group. # p < 0.05, ## p < 0.01, ### p < 0.001 vs. the CYP + DMSO group. && p < 0.01, &&& p < 0.001 vs. the ANA-12 (0.5mg/kg) group
K252a Trka, supplied by U73122 PLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/k252+a/k252a+trka/pmc03306234-172-9-19
Average 90 stars, based on 1 article reviews
k252a trka - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
FUJIFILM k252a
Changes in the mechanical threshold after antagonist administration. a Compared to the CYP + DMSO groups, ANA-12 (0.5 mg/kg), and ANA-12 (1.0 mg/kg) treated every other day after CYP injection reduced the decrease in the mechanical threshold and accelerated recovery significantly, while there was no difference between ANA-12 (0.1 mg/kg) and CYP + DMSO group. There was difference between ANA-12 (0.5 mg/kg) and ANA-12 (1.0 mg/kg) only at day 7, day 10, day 13. b Compared to the CYP+DMSO groups, ANA-12 (0.5 mg/kg), and <t>K252a</t> treated every other day after CYP injection reduced the decrease of the mechanical threshold and accelerated recovery significantly, and there was no difference between the effects of ANA-12 (0.5 mg/kg) and K252a. c ANA-12 treated next day after the third CYP injection 3 days continuously could reverse the mechanical threshold rapidly. d ANA-12 treated one day prior to CYP injection could prevent the onset of allodynia; moreover, there was no significant difference when compared with the control group. All data were analyzed using a two-way analysis of variance (ANOVA) followed by the Sidak's multiple comparisons test. All data were calculated as mean ± SEM ( n = 10 per group). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. the control group. # p < 0.05, ## p < 0.01, ### p < 0.001 vs. the CYP + DMSO group. && p < 0.01, &&& p < 0.001 vs. the ANA-12 (0.5mg/kg) group
K252a, supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/k252+a/k252a/pm15509849-158-3-7
Average 90 stars, based on 1 article reviews
k252a - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
HAKKO CO LTD k252a
A, to the left is shown the time course of the frequency of mEPSCs. The frequency was measured every 30 s. BDNF and <t>K252a</t> were applied to this cell at 200 ng ml−1 and 200 nm, respectively, during the periods indicated by horizontal bars. To the right are shown cumulative plots of the amplitude distributions of mEPSCs 2–5 min before (continuous line) and 17–20 min after (dotted line) the BDNF application. Bin width is 2 pA. The total number of events before and after the BDNF application is 572 and 587, respectively. Other conventions are the same as in Fig. 1D. B, to the left is shown the time course of the frequency of mEPSCs. BDNF and anti-BDNF antibody were applied to this cell at 200 ng ml−1 and 5 μg ml−1, respectively, during the periods indicated by the horizontal bars. To the right are shown cumulative plots of the amplitude distributions of mEPSCs 2–5 min before (continuous line) and 17–20 min after (dotted line) the BDNF application. The total number of events is 452 and 464, respectively. Other conventions are the same as in Fig. 1D.
K252a, supplied by HAKKO CO LTD, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/k252+a/k252a/pmc02270088-61-21-23
Average 90 stars, based on 1 article reviews
k252a - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
LC Laboratories k252a
A, to the left is shown the time course of the frequency of mEPSCs. The frequency was measured every 30 s. BDNF and <t>K252a</t> were applied to this cell at 200 ng ml−1 and 200 nm, respectively, during the periods indicated by horizontal bars. To the right are shown cumulative plots of the amplitude distributions of mEPSCs 2–5 min before (continuous line) and 17–20 min after (dotted line) the BDNF application. Bin width is 2 pA. The total number of events before and after the BDNF application is 572 and 587, respectively. Other conventions are the same as in Fig. 1D. B, to the left is shown the time course of the frequency of mEPSCs. BDNF and anti-BDNF antibody were applied to this cell at 200 ng ml−1 and 5 μg ml−1, respectively, during the periods indicated by the horizontal bars. To the right are shown cumulative plots of the amplitude distributions of mEPSCs 2–5 min before (continuous line) and 17–20 min after (dotted line) the BDNF application. The total number of events is 452 and 464, respectively. Other conventions are the same as in Fig. 1D.
K252a, supplied by LC Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/k252+a/k252a/pmc04032177-389-24-25
Average 90 stars, based on 1 article reviews
k252a - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
AG Scientific k252a
KEY RESOURCES TABLE
K252a, supplied by AG Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/k252+a/k252a/pmc06953177-21-0-2
Average 90 stars, based on 1 article reviews
k252a - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Enzo Biochem zardaverdine
KEY RESOURCES TABLE
Zardaverdine, supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/k252+a/k252a/pmc04854304-352-12-15
Average 90 stars, based on 1 article reviews
zardaverdine - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
clea japan inc k252a
KEY RESOURCES TABLE
K252a, supplied by clea japan inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/k252+a/k252a/pm20463055-68-21-30
Average 90 stars, based on 1 article reviews
k252a - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Changes in the mechanical threshold after antagonist administration. a Compared to the CYP + DMSO groups, ANA-12 (0.5 mg/kg), and ANA-12 (1.0 mg/kg) treated every other day after CYP injection reduced the decrease in the mechanical threshold and accelerated recovery significantly, while there was no difference between ANA-12 (0.1 mg/kg) and CYP + DMSO group. There was difference between ANA-12 (0.5 mg/kg) and ANA-12 (1.0 mg/kg) only at day 7, day 10, day 13. b Compared to the CYP+DMSO groups, ANA-12 (0.5 mg/kg), and K252a treated every other day after CYP injection reduced the decrease of the mechanical threshold and accelerated recovery significantly, and there was no difference between the effects of ANA-12 (0.5 mg/kg) and K252a. c ANA-12 treated next day after the third CYP injection 3 days continuously could reverse the mechanical threshold rapidly. d ANA-12 treated one day prior to CYP injection could prevent the onset of allodynia; moreover, there was no significant difference when compared with the control group. All data were analyzed using a two-way analysis of variance (ANOVA) followed by the Sidak's multiple comparisons test. All data were calculated as mean ± SEM ( n = 10 per group). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. the control group. # p < 0.05, ## p < 0.01, ### p < 0.001 vs. the CYP + DMSO group. && p < 0.01, &&& p < 0.001 vs. the ANA-12 (0.5mg/kg) group

Journal: Journal of Neuroinflammation

Article Title: BDNF promotes activation of astrocytes and microglia contributing to neuroinflammation and mechanical allodynia in cyclophosphamide-induced cystitis

doi: 10.1186/s12974-020-1704-0

Figure Lengend Snippet: Changes in the mechanical threshold after antagonist administration. a Compared to the CYP + DMSO groups, ANA-12 (0.5 mg/kg), and ANA-12 (1.0 mg/kg) treated every other day after CYP injection reduced the decrease in the mechanical threshold and accelerated recovery significantly, while there was no difference between ANA-12 (0.1 mg/kg) and CYP + DMSO group. There was difference between ANA-12 (0.5 mg/kg) and ANA-12 (1.0 mg/kg) only at day 7, day 10, day 13. b Compared to the CYP+DMSO groups, ANA-12 (0.5 mg/kg), and K252a treated every other day after CYP injection reduced the decrease of the mechanical threshold and accelerated recovery significantly, and there was no difference between the effects of ANA-12 (0.5 mg/kg) and K252a. c ANA-12 treated next day after the third CYP injection 3 days continuously could reverse the mechanical threshold rapidly. d ANA-12 treated one day prior to CYP injection could prevent the onset of allodynia; moreover, there was no significant difference when compared with the control group. All data were analyzed using a two-way analysis of variance (ANOVA) followed by the Sidak's multiple comparisons test. All data were calculated as mean ± SEM ( n = 10 per group). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. the control group. # p < 0.05, ## p < 0.01, ### p < 0.001 vs. the CYP + DMSO group. && p < 0.01, &&& p < 0.001 vs. the ANA-12 (0.5mg/kg) group

Article Snippet: K252a (2 μg/10 μL/rat; #12754, Cell Signaling Technology), injected intrathecally (i.t.), was dissolved in 10% DMSO [ ].

Techniques: Injection, Control

A, to the left is shown the time course of the frequency of mEPSCs. The frequency was measured every 30 s. BDNF and K252a were applied to this cell at 200 ng ml−1 and 200 nm, respectively, during the periods indicated by horizontal bars. To the right are shown cumulative plots of the amplitude distributions of mEPSCs 2–5 min before (continuous line) and 17–20 min after (dotted line) the BDNF application. Bin width is 2 pA. The total number of events before and after the BDNF application is 572 and 587, respectively. Other conventions are the same as in Fig. 1D. B, to the left is shown the time course of the frequency of mEPSCs. BDNF and anti-BDNF antibody were applied to this cell at 200 ng ml−1 and 5 μg ml−1, respectively, during the periods indicated by the horizontal bars. To the right are shown cumulative plots of the amplitude distributions of mEPSCs 2–5 min before (continuous line) and 17–20 min after (dotted line) the BDNF application. The total number of events is 452 and 464, respectively. Other conventions are the same as in Fig. 1D.

Journal:

Article Title: Actions of brain-derived neurotrophic factor on evoked and spontaneous EPSCs dissociate with maturation of neurones cultured from rat visual cortex

doi: 10.1111/j.1469-7793.2000.t01-1-00579.x

Figure Lengend Snippet: A, to the left is shown the time course of the frequency of mEPSCs. The frequency was measured every 30 s. BDNF and K252a were applied to this cell at 200 ng ml−1 and 200 nm, respectively, during the periods indicated by horizontal bars. To the right are shown cumulative plots of the amplitude distributions of mEPSCs 2–5 min before (continuous line) and 17–20 min after (dotted line) the BDNF application. Bin width is 2 pA. The total number of events before and after the BDNF application is 572 and 587, respectively. Other conventions are the same as in Fig. 1D. B, to the left is shown the time course of the frequency of mEPSCs. BDNF and anti-BDNF antibody were applied to this cell at 200 ng ml−1 and 5 μg ml−1, respectively, during the periods indicated by the horizontal bars. To the right are shown cumulative plots of the amplitude distributions of mEPSCs 2–5 min before (continuous line) and 17–20 min after (dotted line) the BDNF application. The total number of events is 452 and 464, respectively. Other conventions are the same as in Fig. 1D.

Article Snippet: Application of BDNF and drugs In most of the experiments, recombinant human BDNF (provided from Sumitomo Pharmaceutical Co., Ltd, Japan), or K252a (Kyowa Hakko Co., Ltd, Japan) was applied to neurones through the perfusion medium 10–15 min after the initiation of recordings.

Techniques:

Ratio of the frequency of mEPSCs during the application of BDNF alone, BDNF + K252a and BDNF + anti-BDNF antibody to the respective control value at the time points shown on the abscissa. Filled symbols with vertical bars represent means and twice the s.d. for the same group of cells.

Journal:

Article Title: Actions of brain-derived neurotrophic factor on evoked and spontaneous EPSCs dissociate with maturation of neurones cultured from rat visual cortex

doi: 10.1111/j.1469-7793.2000.t01-1-00579.x

Figure Lengend Snippet: Ratio of the frequency of mEPSCs during the application of BDNF alone, BDNF + K252a and BDNF + anti-BDNF antibody to the respective control value at the time points shown on the abscissa. Filled symbols with vertical bars represent means and twice the s.d. for the same group of cells.

Article Snippet: Application of BDNF and drugs In most of the experiments, recombinant human BDNF (provided from Sumitomo Pharmaceutical Co., Ltd, Japan), or K252a (Kyowa Hakko Co., Ltd, Japan) was applied to neurones through the perfusion medium 10–15 min after the initiation of recordings.

Techniques:

KEY RESOURCES TABLE

Journal: Current biology : CB

Article Title: The receptor kinases BAK1/SERK4 regulate Ca 2+ channel-mediated cellular homeostasis for cell death containment

doi: 10.1016/j.cub.2019.09.018

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: K252a , AG Scientific , Cat #133407-82-6.

Techniques: Virus, Recombinant, RNA Extraction, Reverse Transcription, SYBR Green Assay, Cloning, Mutagenesis, Software